Trials / Recruiting
RecruitingNCT06654440
A Trial of SHR-A2102 for Treatment of Advanced Gynecological Malignancy
An Open-label, Multicenter Phase II Clinical Study of SHR-A2102 for Injection in the Treatment of Advanced Gynaecological Malignancies
- Status
- Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 100 (estimated)
- Sponsor
- Shanghai Hengrui Pharmaceutical Co., Ltd. · Industry
- Sex
- Female
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
The main objective of this study is to evaluate the effectiveness and safety of SHR-A2102 for participants with advanced gynaecological cancer.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | SHR-A2102 for injection | SHR-A2102 for injection |
Timeline
- Start date
- 2024-11-15
- Primary completion
- 2025-08-31
- Completion
- 2026-10-31
- First posted
- 2024-10-23
- Last updated
- 2024-12-10
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT06654440. Inclusion in this directory is not an endorsement.